The award is granted on an annual basis to the best pharma support program in oncology, neurology, and immunology based on ratings from doctors and their support staff
BMS is recognized as the overall best company for its portfolio of drugs in both its hematology and solid tumor offerings. Technology is one of the areas they excelled & received top scores to drive customer experience.
Genentech received top scores in every rated category from both the neurologists and their support staff. They went above & beyond to provide superior services to ensure patients can make it to & afford the treatment.
AbbVie continues to receive top scores for their field engagements and are also receiving positive feedback on their educational materials used to educate the patients.
Daiichi-Sankyo is rating high on their ability to provide an excellent end-to-end patient experience to their patients
Neurocrine is running a program that is considered easy to use and work with having less administrative burden according to the support staff
Incyte is receiving excellent scores for its ability to maintain a strong culture among their hub and field force that engages with the support staff
AZ improved their standings in oncology compared to previous year which in part was driven by their ability to create a strong awareness around their support offerings
Biogen gained its second consecutive win in neurology which was driven by the strong ratings from the physicians who found Biogen easy to work with
AbbVie gathered strong scores across all three sub-categories (rheumatology, dermatology, gastroenterology) with an extra credit to their field scores
Pfizer received top ratings in oncology from the support staff where its field reps and technology solutions were highlighted as top qualities
Biogen won the first annual neurology award in part due to their dedication to go above and beyond to support their patients and work with the offices
The winners are selected based on feedback from doctors and their support staff across the oncology, neurology, and immunology therapeutic areas. The pharma support programs are evaluated based on their performance ratings against the 7 PURE indices in addition to unaided feedback on best/worst-in-class nominations by the HCPs.
The PURE Report was selected as a Global Health & Pharma 2022 Award recipient due to the unique ability of its research to reshape the pharmaceutical manufacturers’ approach to enhance the patients and healthcare providers’ treatment experience within the treatment care areas of oncology, neurology, and immunology.